Editorial - Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents.

Izzi, A; Messina, V; Rinaldi, L; Maggi, P

Izzi, A; Messina, V; Rinaldi, L; Maggi, P.

Izzi A; Department of Infectious Disease and Emergency Infectious Diseases, D. Cotugno Hospital, Azienda Ospedaliera dei Colli, Naples, Italy. izziantonio@yahoo.it.

Eur Rev Med Pharmacol Sci ; 24(10): 5193-5194, 2020 05.

Article in English | MEDLINE | ID: covidwho-561506

Subject(s)

Antiviral Agents/therapeutic use; Carbamates/therapeutic use; Coronavirus Infections/drug therapy; Heterocyclic Compounds, 4 or More Rings/therapeutic use; Pneumonia, Viral/drug therapy; Sofosbuvir/therapeutic use; Antiviral Agents/chemistry; Antiviral Agents/metabolism; Betacoronavirus/isolation & purification; COVID-19; Coronavirus Infections/virology; DNA-Directed DNA Polymerase/chemistry; DNA-Directed DNA Polymerase/metabolism; Drug Therapy, Combination; Humans; Pandemics; Pneumonia, Viral/virology; SARS-CoV-2; Sofosbuvir/chemistry; Sofosbuvir/metabolism; Viral Proteins/chemistry; Viral Proteins/metabolism

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Carbamates / Coronavirus Infections / Sofosbuvir / Heterocyclic Compounds, 4 or More Rings Limits: Humans Language: English Journal: Eur Rev Med Pharmacol Sci Journal subject: Pharmacology / Toxicology Year: 2020 Document Type: Article Affiliation country: Eurrev_202005_21297

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google